title: Variations in Mre11/Rad50/Nbs1 status and DNA damage-induced S-phase arrest in the cell lines of the NCI60 panel.
abstract: BACKGROUND
  The Mre11/Rad50/Nbs1 (MRN) complex is a regulator of cell cycle checkpoints and DNA repair. Defects in MRN can lead to defective S-phase arrest when cells are damaged. Such defects may elicit sensitivity to selected drugs providing a chemical synthetic lethal interaction that could be used to target therapy to tumors with these defects. The goal of this study was to identify these defects in the NCI60 panel of cell lines and identify compounds that might elicit selective cytotoxicity.
  
  
  METHODS
  We screened the NCI60 panel in search of cell lines that express low levels of MRN proteins, or that fail to arrest in S-phase in response to the topisomerase I inhibitor SN38. The NCI COMPARE program was used to discover compounds that preferentially target cells with these phenotypes.
  
  
  RESULTS
  HCT116 cells were initially identified as defective in MRN and S phase arrest. Transfection with Mre11 also elevated Rad50 and Nbs1, and rescued the defective S-phase arrest. Cells of the NCI60 panel exhibited a large range of protein expression but a strong correlation existed between Mre11, Rad50 and Nbs1 consistent with complex formation determining protein stability. Mre11 mRNA correlated best with protein level suggesting it was the primary determinant of the overall level of the complex. Three other cell lines failed to arrest in response to SN38, two of which also had low MRN. However, other cell lines with low MRN still arrested suggesting low MRN does not predict an inability to arrest. Many compounds, including a family of benzothiazoles, correlated with the failure to arrest in S phase. The activity of benzothiazoles has been attributed to metabolic activation and DNA alkylation, but we note several cell lines in which sensitivity does not correlate with metabolism. We propose that the checkpoint defect imposes an additional mechanism of sensitivity on cells.
  
  
  CONCLUSIONS
  We have identified cells with possible defects in the MRN complex and S phase arrest, and a series of compounds that may preferentially target S phase-defective cells. We discuss limitations of the COMPARE program when attempting to identify compounds that selectively inhibit only a few cell lines.
authors: Department of Pharmacology and Toxicology, and Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA.
authors: Kristen M
authors: KM
authors: Garner
authors: Alan
authors: A
authors: Eastman
references: Cancer Res. 2001 Jan 1;61(1):23-6
references: 11196167
references: Nat Cell Biol. 2006 Jan;8(1):37-45
references: 16327781
references: Science. 2005 Apr 22;308(5721):551-4
references: 15790808
references: Otolaryngol Head Neck Surg. 2004 Oct;131(4):477-84
references: 15467621
references: Leukemia. 2002 Apr;16(4):520-6
references: 11960328
references: Br J Cancer. 2003 Feb 10;88(3):470-7
references: 12569393
references: Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1968-72
references: 2000400
references: J Biol Chem. 2006 Oct 13;281(41):30814-23
references: 16905549
references: Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7376-81
references: 10377422
references: Nat Rev Cancer. 2006 Oct;6(10):789-802
references: 16990856
references: EMBO Rep. 2002 Mar;3(3):248-54
references: 11850399
references: J Med Chem. 2008 Aug 28;51(16):5135-9
references: 18666770
references: Science. 1989 Nov 3;246(4930):629-34
references: 2683079
references: Mol Biol Cell. 2008 Apr;19(4):1693-705
references: 18256278
references: Clin Cancer Res. 2008 Sep 1;14(17):5476-83
references: 18765539
references: Mol Cancer Ther. 2008 Feb;7(2):252-62
references: 18281511
references: J Biol Chem. 2006 Apr 7;281(14):9346-50
references: 16431910
references: Science. 2000 May 26;288(5470):1425-9
references: 10827953
references: Cell. 2009 Mar 6;136(5):823-37
references: 19269363
references: Cell Cycle. 2008 Jun 1;7(11):1668-77
references: 18469532
references: J Mol Graph Model. 2002 Jan;20(4):297-303
references: 11858638
references: Cell. 1999 Dec 10;99(6):577-87
references: 10612394
references: Nature. 2001 Apr 12;410(6830):842-7
references: 11298456
references: Hum Genet. 1989 May;82(2):113-7
references: 2722185
references: J Med Chem. 1999 Oct 7;42(20):4172-84
references: 10514287
references: Cancer Chemother Pharmacol. 2000;46(6):507-16
references: 11138465
references: Anal Biochem. 1992 Nov 15;207(1):186-92
references: 1489093
references: Science. 1997 Jan 17;275(5298):343-9
references: 8994024